News Releases

Date Title and Summary
Toggle Summary Court Decides It Lacks Jurisdiction Before FDA Approval Occurs
SEATTLE --(BUSINESS WIRE)--Jun. 14, 2017-- Juno Therapeutics, Inc. (NASDAQ: JUNO), a biopharmaceutical company developing innovative cellular immunotherapies for the treatment of cancer, announced today that the U.S. District Court for the District of Delaware decided it lacked jurisdiction at this
Toggle Summary Juno Therapeutics to Present at the Goldman Sachs 38th Annual Global Healthcare Conference
SEATTLE --(BUSINESS WIRE)--Jun. 6, 2017-- Juno Therapeutics, Inc. (NASDAQ: JUNO) today announced that it will webcast its presentation at the Goldman Sachs 38 th Annual Global Healthcare Conference at 10:00 a.m. PT on Tuesday, June 13, 2017 . The presentation will feature a business overview and
Toggle Summary Juno Therapeutics Presents Updated TRANSCEND NHL 001 Trial Data Demonstrating High Durable Response Rates in Patients with Relapsed or Refractory CD19+ Aggressive Non-Hodgkin Lymphoma
– First multicenter CAR T trial to treat a wide range of patients with aggressive relapsed or refractory NHL excluded from other trials – 66% (21/32) overall response rate and 50% (16/32) complete response at three months in core analysis group moving into pivotal trial; 90% (9/10) of those
Toggle Summary Juno Therapeutics Appoints Jay Flatley to Board of Directors
SEATTLE --(BUSINESS WIRE)--May 23, 2017-- Juno Therapeutics, Inc. (NASDAQ: JUNO), a biopharmaceutical company developing innovative cellular immunotherapies for the treatment of cancer, today announced it has appointed Jay Flatley to its Board of Directors. Mr.
Toggle Summary Juno Therapeutics to Present Key Clinical Data Updates on JCAR017 and JCAR014 at the 2017 American Society of Clinical Oncology Annual Meeting
SEATTLE --(BUSINESS WIRE)--May 17, 2017-- Juno Therapeutics, Inc. (NASDAQ: JUNO), a biopharmaceutical company developing innovative cellular immunotherapies for the treatment of cancer, today announced that it will present key clinical updates in partnership with its collaborators on its
Toggle Summary Juno Therapeutics to Present at the Bank of America Merrill Lynch 2017 Health Care Conference
SEATTLE --(BUSINESS WIRE)--May 9, 2017-- Juno Therapeutics, Inc. (NASDAQ: JUNO) today announced that it will webcast its presentation at the Bank of America Merrill Lynch 2017 Health Care Conference at 3:40 p.m. PT on Tuesday, May 16, 2017 . The presentation will feature a business overview and
Toggle Summary Juno Therapeutics Reports First Quarter 2017 Financial Results
– Initiated five trials with new binders, technologies, and targets – – 2017 cash burn and operating burn guidance reaffirmed – – Added key talent to leadership team – – Eleven product candidates in clinical trials against eight different targets – – Strong cash position of $850.7 million – –
Toggle Summary Juno Therapeutics to Report First Quarter 2017 Financial Results on Thursday, May 4
SEATTLE --(BUSINESS WIRE)--Apr. 27, 2017-- Juno Therapeutics, Inc. (NASDAQ: JUNO) will announce financial results for the first quarter 2017 on Thursday, May 4, 2017 , after the close of U.S.-based financial markets. Following the announcement, Juno management will host a conference call and live
Toggle Summary Juno Therapeutics Appoints Rupert Vessey to Board of Directors
SEATTLE --(BUSINESS WIRE)--Apr. 19, 2017-- Juno Therapeutics, Inc. (NASDAQ: JUNO), a biopharmaceutical company developing innovative cellular immunotherapies for the treatment of cancer, today announced it has appointed to its Board of Directors Dr. Rupert Vessey , President of Research and Early
Toggle Summary Juno Therapeutics Appoints Sunil Agarwal as President of Research and Development
Experienced executive addition with proven leadership and drug development expertise in emerging fields of medicine SEATTLE --(BUSINESS WIRE)--Apr. 17, 2017-- Juno Therapeutics, Inc. (NASDAQ: JUNO), a biopharmaceutical company developing innovative cellular immunotherapies for the treatment of